Could a common diabetes drug mend hearts after failure?
NCT ID NCT07403955
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether dapagliflozin, a drug already used for diabetes, can improve heart function in people hospitalized with acute heart failure. About 188 participants will take the drug or not for three months, and doctors will use special ultrasound imaging to measure changes in heart muscle strain. The goal is to see if the drug helps the heart remodel and pump better after a crisis.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
dapagliflozin (a diabetes drug being tested for heart failure)
What this could lead to
If it works, this could show that dapagliflozin helps the heart recover better after acute failure, potentially leading to a new standard treatment.
What could go wrong
This is a small, early-stage study (188 people) that has not yet started. It only measures heart strain on imaging, not long-term outcomes like survival. The drug may not show meaningful benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE HEART FAILURE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.